Janux Therapeutics, Inc. (JANX) — Analyst outlook / Analyst consensus target is. Based on 13 analyst ratings, the consensus is bullish — 11 Buy, 2 Hold.
The consensus price target is $39.80 (low: $29.00, high: $57.00), representing an upside of 161.2% from the current price $15.24.
Analysts estimate Earnings Per Share (EPS) of $-1.46 and revenue of $0.01B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.28 vs est $-1.46 (beat +12.4%). 2025: actual $-1.83 vs est $-1.98 (beat +7.4%). Analyst accuracy: 89%.
JANX Stock — 12-Month Price Forecast
$39.80
▲ +161.15% Upside
Average Price Target
Based on 13 Wall Street analysts offering 12-month price targets for Janux Therapeutics, Inc., the average price target is $39.80, with a high forecast of $57.00, and a low forecast of $29.00.
The average price target represents a +161.15% change from the last price of $15.24.
Highest Price Target
$57.00
Average Price Target
$39.80
Lowest Price Target
$29.00
JANX Analyst Ratings
Buy
Based on 13 analysts giving stock ratings to Janux Therapeutics, Inc. in the past 3 months
EPS Estimates — JANX
89%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.28
vs Est –$1.46
▲ 14.2% off
2025
Actual –$1.83
vs Est –$1.98
▲ 8.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — JANX
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.011B
vs Est $0.011B
▼ 3.8% off
2025
Actual $0.010B
vs Est $0.010B
▼ 0.6% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
